Randomized Trials Underway For Renal Denervation To Treat Hypertension
This article was originally published in The Gray Sheet
Executive Summary
Ardian is moving forward with a prospective randomized clinical trial to study its Symplicity radiofrequency catheter for ablation of the sympathetic renal nerves to treat chronic hypertension, following successful results of its first-in-man study
You may also be interested in...
Ardian Targets 2011 For First Launch Of RF Catheter That Treats Hypertension
Ardian plans to introduce the first catheter-based treatment for uncontrolled hypertension in Europe by 2011 and in the U.S. by 2013
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.